$AWH
Aspira Women's Health Inc.

2023 Q1 Form 10-K Financial Statement

#000092661723000026 Filed on March 30, 2023

View on sec.gov

Income Statement

Concept 2023 Q1 2022 Q4 2022
Revenue $2.316M $2.153M $8.184M
YoY Change 22.35% 16.32% 20.14%
Cost Of Revenue $1.125M $917.0K $3.865M
YoY Change 20.71% 9.56% 3.07%
Gross Profit $1.191M $1.236M $4.319M
YoY Change 23.93% 21.89% 41.05%
Gross Profit Margin 51.42% 57.41% 52.77%
Selling, General & Admin $5.729M $5.799M $31.13M
YoY Change -35.34% -31.83% 2.6%
% of Gross Profit 481.02% 469.17% 720.79%
Research & Development $1.231M $1.038M $5.953M
YoY Change -8.68% -28.56% 12.02%
% of Gross Profit 103.36% 83.98% 137.83%
Depreciation & Amortization $70.00K $69.00K $264.0K
YoY Change 9.38% 7.81% -12.58%
% of Gross Profit 5.88% 5.58% 6.11%
Operating Expenses $6.960M $6.837M $37.08M
YoY Change -31.82% -31.36% 4.0%
Operating Profit -$5.769M -$5.601M -$32.76M
YoY Change -37.61% -37.39% 0.52%
Interest Expense $26.00K $27.00K $17.00K
YoY Change -244.44% -307.69% -135.42%
% of Operating Profit
Other Income/Expense, Net -$300.0K $473.0K $5.578M
YoY Change 9900.0% -23750.0% 468.6%
Pretax Income -$6.067M -$5.101M -$27.17M
YoY Change -34.54% -43.08% -185.81%
Income Tax
% Of Pretax Income
Net Earnings -$6.067M -$5.101M -$27.17M
YoY Change -34.54% -43.08% -14.19%
Net Earnings / Revenue -261.96% -236.93% -331.99%
Basic Earnings Per Share -$0.73 -$0.23
Diluted Earnings Per Share -$0.73 -$0.04 -$0.23
COMMON SHARES
Basic Shares Outstanding 124.9M 124.4M 116.5M
Diluted Shares Outstanding 8.313M 116.5M

Balance Sheet

Concept 2023 Q1 2022 Q4 2022
SHORT-TERM ASSETS
Cash & Short-Term Investments $7.535M $13.31M $13.31M
YoY Change -71.94% -64.21% -64.21%
Cash & Equivalents $7.535M $13.31M $13.31M
Short-Term Investments
Other Short-Term Assets $1.137M $1.442M $1.442M
YoY Change -29.81% -11.21% -11.21%
Inventory $302.0K $316.0K $316.0K
Prepaid Expenses
Receivables $1.554M $1.245M $1.245M
Other Receivables $0.00 $0.00 $0.00
Total Short-Term Assets $10.53M $16.31M $16.31M
YoY Change -64.67% -59.23% -59.23%
LONG-TERM ASSETS
Property, Plant & Equipment $305.0K $650.0K $650.0K
YoY Change -36.46% 40.09% -19.75%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets $145.0K $414.0K $414.0K
YoY Change -42.0% 2857.14% 56.82%
Total Long-Term Assets $968.0K $1.064M $1.064M
YoY Change -8.77% -0.93% -0.93%
TOTAL ASSETS
Total Short-Term Assets $10.53M $16.31M $16.31M
Total Long-Term Assets $968.0K $1.064M $1.064M
Total Assets $11.50M $17.37M $17.37M
YoY Change -62.75% -57.71% -57.71%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $867.0K $881.0K $881.0K
YoY Change -33.2% -41.31% -41.31%
Accrued Expenses $3.984M $3.727M $3.727M
YoY Change -1.26% -29.67% -30.45%
Deferred Revenue
YoY Change
Short-Term Debt $535.0K $764.0K $764.0K
YoY Change 3.08% -1.93% -1.93%
Long-Term Debt Due $442.0K $403.0K $403.0K
YoY Change 98.21% 100.5% 100.5%
Total Short-Term Liabilities $5.911M $5.775M $5.775M
YoY Change -3.71% -26.34% -26.34%
LONG-TERM LIABILITIES
Long-Term Debt $2.204M $2.315M $2.315M
YoY Change -16.7% -14.83% -14.83%
Other Long-Term Liabilities $2.554M $2.552M $2.552M
YoY Change 669.28% 631.23% 631.23%
Total Long-Term Liabilities $2.204M $4.867M $4.867M
YoY Change -16.7% 79.07% 58.69%
TOTAL LIABILITIES
Total Short-Term Liabilities $5.911M $5.775M $5.775M
Total Long-Term Liabilities $2.204M $4.867M $4.867M
Total Liabilities $10.67M $10.64M $10.64M
YoY Change 17.02% -2.43% -2.43%
SHAREHOLDERS EQUITY
Retained Earnings -$505.0M -$498.9M
YoY Change 4.98% 5.76%
Common Stock $8.000K $125.0K
YoY Change -92.86% 11.61%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity $827.0K $6.731M $6.731M
YoY Change
Total Liabilities & Shareholders Equity $11.50M $17.37M $17.37M
YoY Change -62.75% -57.71% -57.71%

Cashflow Statement

Concept 2023 Q1 2022 Q4 2022
OPERATING ACTIVITIES
Net Income -$6.067M -$5.101M -$27.17M
YoY Change -34.54% -43.08% -14.19%
Depreciation, Depletion And Amortization $70.00K $69.00K $264.0K
YoY Change 9.38% 7.81% -12.58%
Cash From Operating Activities -$5.706M -$7.076M -$32.20M
YoY Change -43.91% -7.49% 17.54%
INVESTING ACTIVITIES
Capital Expenditures $8.000K $74.00K $232.0K
YoY Change -90.24% -346.67% 26.09%
Acquisitions
YoY Change
Other Investing Activities
YoY Change
Cash From Investing Activities -$8.000K -$74.00K -$232.0K
YoY Change -90.24% 146.67% 26.09%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities -55.00K -94.00K 8.544M
YoY Change -21.43% 754.55% -82.34%
NET CHANGE
Cash From Operating Activities -5.706M -7.076M -32.20M
Cash From Investing Activities -8.000K -74.00K -232.0K
Cash From Financing Activities -55.00K -94.00K 8.544M
Net Change In Cash -5.769M -7.244M -23.87M
YoY Change -44.13% -5.8% -214.78%
FREE CASH FLOW
Cash From Operating Activities -$5.706M -$7.076M -$32.20M
Capital Expenditures $8.000K $74.00K $232.0K
Free Cash Flow -$5.714M -$7.150M -$32.43M
YoY Change -44.28% -6.16% 17.6%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
CY2022 dei Amendment Flag
AmendmentFlag
false
CY2022 dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
FY
CY2022 dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2022
CY2022 dei Entity Central Index Key
EntityCentralIndexKey
0000926617
CY2021Q4 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2022Q4 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2021Q4 us-gaap Deferred Tax Assets Net
DeferredTaxAssetsNet
CY2022Q4 us-gaap Deferred Tax Assets Net
DeferredTaxAssetsNet
CY2021 us-gaap Dilutive Securities
DilutiveSecurities
CY2022 us-gaap Dilutive Securities
DilutiveSecurities
CY2021 us-gaap Effective Income Tax Rate Continuing Operations
EffectiveIncomeTaxRateContinuingOperations
CY2022 us-gaap Effective Income Tax Rate Continuing Operations
EffectiveIncomeTaxRateContinuingOperations
CY2022 us-gaap Impairment Long Lived Asset Held For Use Statement Of Income Or Comprehensive Income Extensible Enumeration
ImpairmentLongLivedAssetHeldForUseStatementOfIncomeOrComprehensiveIncomeExtensibleEnumeration
http://fasb.org/us-gaap/2022#GeneralAndAdministrativeExpense
CY2022 dei Document Type
DocumentType
10-K
CY2022 dei Document Annual Report
DocumentAnnualReport
true
CY2022 dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--12-31
CY2022 dei Document Period End Date
DocumentPeriodEndDate
2022-12-31
CY2022 dei Document Transition Report
DocumentTransitionReport
false
CY2022 dei Entity File Number
EntityFileNumber
001-34810
CY2022 dei Entity Registrant Name
EntityRegistrantName
Aspira Women’s Health Inc.
CY2022 dei Entity Incorporation State Country Code
EntityIncorporationStateCountryCode
DE
CY2022 dei Entity Tax Identification Number
EntityTaxIdentificationNumber
33-0595156
CY2022 dei Entity Address Address Line1
EntityAddressAddressLine1
12117 Bee Caves Road
CY2022 dei Entity Address Address Line2
EntityAddressAddressLine2
Building III
CY2022 dei Entity Address Address Line3
EntityAddressAddressLine3
Suite 100
CY2022 dei Entity Address City Or Town
EntityAddressCityOrTown
Austin
CY2022 dei Entity Address State Or Province
EntityAddressStateOrProvince
TX
CY2022 dei Entity Address Postal Zip Code
EntityAddressPostalZipCode
78738
CY2022 dei City Area Code
CityAreaCode
512
CY2022 dei Local Phone Number
LocalPhoneNumber
519-0400
CY2022 dei Security12b Title
Security12bTitle
Common Stock, par value $0.001 per share
CY2022 dei Trading Symbol
TradingSymbol
AWH
CY2022 dei Security Exchange Name
SecurityExchangeName
NASDAQ
CY2022 dei Entity Well Known Seasoned Issuer
EntityWellKnownSeasonedIssuer
No
CY2022 dei Entity Voluntary Filers
EntityVoluntaryFilers
No
CY2022 dei Entity Current Reporting Status
EntityCurrentReportingStatus
Yes
CY2022 dei Entity Interactive Data Current
EntityInteractiveDataCurrent
Yes
CY2022 dei Entity Filer Category
EntityFilerCategory
Non-accelerated Filer
CY2022 dei Entity Small Business
EntitySmallBusiness
true
CY2022 dei Entity Emerging Growth Company
EntityEmergingGrowthCompany
false
CY2022 dei Icfr Auditor Attestation Flag
IcfrAuditorAttestationFlag
false
CY2022 dei Entity Shell Company
EntityShellCompany
false
CY2022Q2 dei Entity Public Float
EntityPublicFloat
50183661
CY2023Q1 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
124943144
CY2022 dei Auditor Firm
AuditorFirmId
243
CY2022 dei Auditor Name
AuditorName
BDO USA, LLP
CY2022 dei Auditor Location
AuditorLocation
Woodbridge, New Jersey
CY2022Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
13306000
CY2021Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
37180000
CY2022Q4 us-gaap Allowance For Doubtful Accounts Receivable
AllowanceForDoubtfulAccountsReceivable
9000
CY2021Q4 us-gaap Allowance For Doubtful Accounts Receivable
AllowanceForDoubtfulAccountsReceivable
23000
CY2022Q4 us-gaap Accounts Receivable Net Current
AccountsReceivableNetCurrent
1245000
CY2021Q4 us-gaap Accounts Receivable Net Current
AccountsReceivableNetCurrent
1027000
CY2022Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
1442000
CY2021Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
1624000
CY2022Q4 us-gaap Inventory Net
InventoryNet
316000
CY2021Q4 us-gaap Inventory Net
InventoryNet
174000
CY2022Q4 us-gaap Assets Current
AssetsCurrent
16309000
CY2021Q4 us-gaap Assets Current
AssetsCurrent
40005000
CY2022Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
368000
CY2021Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
464000
CY2022Q4 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
282000
CY2021Q4 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
346000
CY2022Q4 us-gaap Restricted Cash Noncurrent
RestrictedCashNoncurrent
251000
CY2021Q4 us-gaap Restricted Cash Noncurrent
RestrictedCashNoncurrent
250000
CY2022Q4 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
163000
CY2021Q4 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
14000
CY2022Q4 us-gaap Assets
Assets
17373000
CY2021Q4 us-gaap Assets
Assets
41079000
CY2022Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
881000
CY2021Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
1501000
CY2022Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
3650000
CY2021Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
5299000
CY2022Q4 us-gaap Long Term Debt Current
LongTermDebtCurrent
403000
CY2021Q4 us-gaap Long Term Debt Current
LongTermDebtCurrent
201000
CY2022Q4 us-gaap Short Term Borrowings
ShortTermBorrowings
764000
CY2021Q4 us-gaap Short Term Borrowings
ShortTermBorrowings
779000
CY2022Q4 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
77000
CY2021Q4 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
60000
CY2022Q4 us-gaap Liabilities Current
LiabilitiesCurrent
5775000
CY2021Q4 us-gaap Liabilities Current
LiabilitiesCurrent
7840000
CY2022Q4 us-gaap Long Term Debt Noncurrent
LongTermDebtNoncurrent
2315000
CY2021Q4 us-gaap Long Term Debt Noncurrent
LongTermDebtNoncurrent
2718000
CY2022Q4 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
272000
CY2021Q4 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
349000
CY2022Q4 us-gaap Warrants And Rights Outstanding
WarrantsAndRightsOutstanding
2280000
CY2022Q4 us-gaap Liabilities
Liabilities
10642000
CY2021Q4 us-gaap Liabilities
Liabilities
10907000
CY2021Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2022Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2021Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
150000000
CY2022Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
150000000
CY2022Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
124594888
CY2022Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
124594888
CY2021Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
112138741
CY2021Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
112138741
CY2022Q4 us-gaap Common Stock Value
CommonStockValue
125000
CY2021Q4 us-gaap Common Stock Value
CommonStockValue
112000
CY2022Q4 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
505504000
CY2021Q4 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
501788000
CY2022Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-498898000
CY2021Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-471728000
CY2022Q4 us-gaap Stockholders Equity
StockholdersEquity
6731000
CY2021Q4 us-gaap Stockholders Equity
StockholdersEquity
30172000
CY2022Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
17373000
CY2021Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
41079000
CY2022 us-gaap Revenues
Revenues
8184000
CY2021 us-gaap Revenues
Revenues
6812000
CY2022 us-gaap Cost Of Goods And Services Sold
CostOfGoodsAndServicesSold
3865000
CY2021 us-gaap Cost Of Goods And Services Sold
CostOfGoodsAndServicesSold
3750000
CY2022 us-gaap Gross Profit
GrossProfit
4319000
CY2021 us-gaap Gross Profit
GrossProfit
3062000
CY2022 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
5953000
CY2021 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
5314000
CY2022 us-gaap Selling And Marketing Expense
SellingAndMarketingExpense
14948000
CY2021 us-gaap Selling And Marketing Expense
SellingAndMarketingExpense
17086000
CY2022 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
16183000
CY2021 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
13257000
CY2022 us-gaap Operating Expenses
OperatingExpenses
37084000
CY2021 us-gaap Operating Expenses
OperatingExpenses
35657000
CY2022 us-gaap Operating Income Loss
OperatingIncomeLoss
-32765000
CY2021 us-gaap Operating Income Loss
OperatingIncomeLoss
-32595000
CY2022 us-gaap Fair Value Adjustment Of Warrants
FairValueAdjustmentOfWarrants
-5472000
CY2022 us-gaap Interest Income Expense Net
InterestIncomeExpenseNet
17000
CY2021 us-gaap Interest Income Expense Net
InterestIncomeExpenseNet
-48000
CY2022 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
106000
CY2021 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
981000
CY2022 us-gaap Net Income Loss
NetIncomeLoss
-27170000
CY2021 us-gaap Net Income Loss
NetIncomeLoss
-31662000
CY2022 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.23
CY2022 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.23
CY2021 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.28
CY2021 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.28
CY2022 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
116536631
CY2022 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
116536631
CY2021 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
111210614
CY2021 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
111210614
CY2020Q4 us-gaap Stockholders Equity
StockholdersEquity
9719000
CY2021 us-gaap Net Income Loss
NetIncomeLoss
-31662000
CY2021 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
718000
CY2021 us-gaap Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
47858000
CY2021 us-gaap Stock Issued During Period Value Restricted Stock Award Net Of Forfeitures
StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures
455000
CY2021 us-gaap Stock Granted During Period Value Sharebased Compensation
StockGrantedDuringPeriodValueSharebasedCompensation
3084000
CY2021Q4 us-gaap Stockholders Equity
StockholdersEquity
30172000
CY2022 us-gaap Net Income Loss
NetIncomeLoss
-27170000
CY2022 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
13000
CY2022 awh Common Stock And Warrants Issued Value
CommonStockAndWarrantsIssuedValue
1040000
CY2022 us-gaap Stock Issued During Period Value Restricted Stock Award Net Of Forfeitures
StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures
363000
CY2022 us-gaap Stock Granted During Period Value Sharebased Compensation
StockGrantedDuringPeriodValueSharebasedCompensation
2313000
CY2022Q4 us-gaap Stockholders Equity
StockholdersEquity
6731000
CY2022 us-gaap Net Income Loss
NetIncomeLoss
-27170000
CY2021 us-gaap Net Income Loss
NetIncomeLoss
-31662000
CY2022 us-gaap Operating Lease Right Of Use Asset Amortization Expense
OperatingLeaseRightOfUseAssetAmortizationExpense
4000
CY2021 us-gaap Operating Lease Right Of Use Asset Amortization Expense
OperatingLeaseRightOfUseAssetAmortizationExpense
37000
CY2022 us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
264000
CY2021 us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
302000
CY2022 us-gaap Share Based Compensation
ShareBasedCompensation
2676000
CY2021 us-gaap Share Based Compensation
ShareBasedCompensation
3539000
CY2022 us-gaap Fair Value Adjustment Of Warrants
FairValueAdjustmentOfWarrants
-5472000
CY2022 us-gaap Gain Loss On Sale Of Property Plant Equipment
GainLossOnSaleOfPropertyPlantEquipment
-64000
CY2021 us-gaap Gain Loss On Sale Of Property Plant Equipment
GainLossOnSaleOfPropertyPlantEquipment
-1000
CY2021 us-gaap Gains Losses On Extinguishment Of Debt
GainsLossesOnExtinguishmentOfDebt
1006000
CY2022 us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
218000
CY2021 us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
162000
CY2022 us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
-33000
CY2021 us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
548000
CY2022 us-gaap Increase Decrease In Inventories
IncreaseDecreaseInInventories
142000
CY2021 us-gaap Increase Decrease In Inventories
IncreaseDecreaseInInventories
144000
CY2022 us-gaap Increase Decrease In Accounts Payable And Accrued Liabilities
IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
-2224000
CY2021 us-gaap Increase Decrease In Accounts Payable And Accrued Liabilities
IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
2248000
CY2022 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-32185000
CY2021 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-27395000
CY2022 us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
232000
CY2021 us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
184000
CY2022 us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-232000
CY2021 us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-184000
CY2022 us-gaap Repayments Of Lines Of Credit
RepaymentsOfLinesOfCredit
261000
CY2021 us-gaap Repayments Of Lines Of Credit
RepaymentsOfLinesOfCredit
198000
CY2022 us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
13000
CY2021 us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
718000
CY2022 us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
9000000
CY2021 us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
48235000
CY2022 us-gaap Payments Of Stock Issuance Costs
PaymentsOfStockIssuanceCosts
208000
CY2021 us-gaap Payments Of Stock Issuance Costs
PaymentsOfStockIssuanceCosts
377000
CY2022 us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
8544000
CY2021 us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
48378000
CY2022 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
-23873000
CY2021 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
20799000
CY2021Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
37430000
CY2020Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
16631000
CY2022Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
13557000
CY2021Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
37430000
CY2022Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
13306000
CY2021Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
37180000
CY2022Q4 us-gaap Restricted Cash Noncurrent
RestrictedCashNoncurrent
251000
CY2021Q4 us-gaap Restricted Cash Noncurrent
RestrictedCashNoncurrent
250000
CY2022Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
13557000
CY2021Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
37430000
CY2022 us-gaap Interest Paid Net
InterestPaidNet
77000
CY2021 us-gaap Interest Paid Net
InterestPaidNet
77000
CY2021 awh Net Increase In Right Of Use Assets
NetIncreaseInRightOfUseAssets
-1006000
CY2022 us-gaap Notes Reduction
NotesReduction
7752000
CY2021Q4 us-gaap Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
1992000
CY2022Q4 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
639000
CY2021Q4 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
273000
CY2022Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
3650000
CY2022Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-498900000
CY2022Q4 awh Working Capital
WorkingCapital
10500000
CY2022 us-gaap Net Income Loss
NetIncomeLoss
-27200000
CY2022 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-32200000
CY2022 us-gaap Use Of Estimates
UseOfEstimates
<span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: italic;font-weight: bold;margin: 0;padding: 0;">Use of Estimates</span><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-indent: 0.50in;"><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">The preparation of consolidated financial statements in accordance with generally accepted accounting principles in the U.S. (“GAAP”) requires management to make estimates and assumptions that affect the amounts reported in the consolidated financial statements and accompanying notes. The primary estimates underlying the Company’s consolidated financial statements include assumptions regarding revenue recognition as well as variables used in calculating the fair value of the Company’s equity awards, warrants, income taxes and contingent liabilities. Changes in estimates and assumptions are reflected in reported results in the period in which they become known. Actual results could differ from those estimates.</span></p>
CY2022 us-gaap Concentration Risk Credit Risk
ConcentrationRiskCreditRisk
<span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: italic;font-weight: bold;margin: 0;padding: 0;">Concentration of Credit Risk</span><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-indent: 0.50in;"><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Financial instruments that potentially subject the Company to a concentration of credit risk consist of cash and cash equivalents and accounts receivable. The Company maintains cash and cash equivalents in recognized financial institutions in the United States. The funds are insured by the FDIC up to a maximum of $250,000, but are otherwise unprotected. The Company has not experienced any losses associated with deposits of cash and cash equivalents. The Company does not invest in derivative instruments or engage in hedging activities.</span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-indent: 0.50in;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p>
CY2021Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
5299000
CY2022 awh Share Based Compensation Arrangement By Share Based Payment Award Number Of Shares Available For Grant Restricted Stock Units Cancelled In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrantRestrictedStockUnitsCancelledInPeriod
5193
CY2022 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Grants In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod
438340
CY2022 us-gaap Finite Lived Intangible Assets Cost Incurred To Renew Or Extend
FiniteLivedIntangibleAssetsCostIncurredToRenewOrExtend
410000
CY2021 us-gaap Finite Lived Intangible Assets Cost Incurred To Renew Or Extend
FiniteLivedIntangibleAssetsCostIncurredToRenewOrExtend
202000
CY2022Q4 us-gaap Lessee Operating Lease Liability Payments Due Year Four
LesseeOperatingLeaseLiabilityPaymentsDueYearFour
64000
CY2022Q4 us-gaap Lessee Operating Lease Liability Payments Due
LesseeOperatingLeaseLiabilityPaymentsDue
409000
CY2022Q4 us-gaap Lessee Operating Lease Liability Undiscounted Excess Amount
LesseeOperatingLeaseLiabilityUndiscountedExcessAmount
60000
CY2022Q4 us-gaap Operating Lease Liability
OperatingLeaseLiability
349000
CY2022Q4 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
77000
CY2022 us-gaap Number Of Reportable Segments
NumberOfReportableSegments
1
CY2022Q4 us-gaap Accounts Payable And Accrued Liabilities Current And Noncurrent
AccountsPayableAndAccruedLiabilitiesCurrentAndNoncurrent
296850
CY2022Q4 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
272000
CY2022Q4 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
3179000
CY2021Q4 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
3249000
CY2022Q4 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
2811000
CY2021Q4 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
2785000
CY2022Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
368000
CY2021Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
464000
CY2022 us-gaap Depreciation
Depreciation
265000
CY2021 us-gaap Depreciation
Depreciation
302000
CY2022 us-gaap Impairment Of Long Lived Assets Held For Use
ImpairmentOfLongLivedAssetsHeldForUse
52000
CY2022Q4 us-gaap Accrued Employee Benefits Current
AccruedEmployeeBenefitsCurrent
2051000
CY2021Q4 us-gaap Accrued Employee Benefits Current
AccruedEmployeeBenefitsCurrent
2652000
CY2022Q4 awh Collaboration And Research Agreement Costs
CollaborationAndResearchAgreementCosts
404000
CY2021Q4 awh Collaboration And Research Agreement Costs
CollaborationAndResearchAgreementCosts
382000
CY2022Q4 us-gaap Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
556000
CY2022Q4 us-gaap Long Term Debt
LongTermDebt
2718000
CY2021Q4 us-gaap Long Term Debt
LongTermDebt
2919000
CY2022Q4 us-gaap Long Term Debt Current
LongTermDebtCurrent
403000
CY2021Q4 us-gaap Long Term Debt Current
LongTermDebtCurrent
201000
CY2022Q4 us-gaap Long Term Debt Noncurrent
LongTermDebtNoncurrent
2315000
CY2021Q4 us-gaap Long Term Debt Noncurrent
LongTermDebtNoncurrent
2718000
CY2022Q4 us-gaap Contractual Obligation
ContractualObligation
2729000
CY2022Q4 us-gaap Contractual Obligation Due In Next Twelve Months
ContractualObligationDueInNextTwelveMonths
406000
CY2022Q4 us-gaap Contractual Obligation Due In Second Year
ContractualObligationDueInSecondYear
452000
CY2022Q4 us-gaap Contractual Obligation Due In Third Year
ContractualObligationDueInThirdYear
461000
CY2022Q4 us-gaap Contractual Obligation Due In Fourth Year
ContractualObligationDueInFourthYear
341000
CY2022Q4 us-gaap Contractual Obligation Due In Fifth Year
ContractualObligationDueInFifthYear
254000
CY2022Q4 us-gaap Contractual Obligation Due After Fifth Year
ContractualObligationDueAfterFifthYear
815000
CY2022Q4 us-gaap Lessee Operating Lease Liability Payments Due Next Twelve Months
LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths
106000
CY2022Q4 us-gaap Lessee Operating Lease Liability Payments Due Year Two
LesseeOperatingLeaseLiabilityPaymentsDueYearTwo
116000
CY2022Q4 us-gaap Lessee Operating Lease Liability Payments Due Year Three
LesseeOperatingLeaseLiabilityPaymentsDueYearThree
123000
CY2022 us-gaap Operating Lease Payments
OperatingLeasePayments
371000
CY2021 us-gaap Operating Lease Payments
OperatingLeasePayments
366000
CY2022Q4 us-gaap Operating Lease Weighted Average Remaining Lease Term1
OperatingLeaseWeightedAverageRemainingLeaseTerm1
P3Y6M
CY2021Q4 us-gaap Operating Lease Weighted Average Remaining Lease Term1
OperatingLeaseWeightedAverageRemainingLeaseTerm1
P4Y6M
CY2022Q4 us-gaap Operating Lease Weighted Average Discount Rate Percent
OperatingLeaseWeightedAverageDiscountRatePercent
0.0930
CY2021Q4 us-gaap Operating Lease Weighted Average Discount Rate Percent
OperatingLeaseWeightedAverageDiscountRatePercent
0.0933
CY2022 us-gaap Royalty Expense
RoyaltyExpense
318000
CY2021 us-gaap Royalty Expense
RoyaltyExpense
263000
CY2022 us-gaap Severance Costs1
SeveranceCosts1
1284000
CY2022 awh Insurance Reimbursement Including Not Paid
InsuranceReimbursementIncludingNotPaid
523000
CY2021Q1 us-gaap Stock Issued During Period Shares New Issues
StockIssuedDuringPeriodSharesNewIssues
6000000
CY2021Q1 us-gaap Shares Issued Price Per Share
SharesIssuedPricePerShare
7.50
CY2021Q1 us-gaap Stock Issued During Period Shares New Issues
StockIssuedDuringPeriodSharesNewIssues
6000000
CY2021Q1 awh Underwriting Commitments Per Share
UnderwritingCommitmentsPerShare
0.4875
CY2021Q1 us-gaap Stock Issued During Period Shares New Issues
StockIssuedDuringPeriodSharesNewIssues
900000
CY2021Q1 awh Underwriting Commitments Per Share
UnderwritingCommitmentsPerShare
0.4875
CY2021Q1 awh Underwriting Commitments Additional Shares Offered
UnderwritingCommitmentsAdditionalSharesOffered
900000
CY2021Q1 us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
47858000
CY2021Q1 us-gaap Payments Of Stock Issuance Costs
PaymentsOfStockIssuanceCosts
377000
CY2022Q3 awh Common Stock And Warrants Issued Shares
CommonStockAndWarrantsIssuedShares
12000000
CY2022Q3 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2022Q3 us-gaap Class Of Warrant Or Right Number Of Securities Called By Each Warrant Or Right
ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight
12000000
CY2022Q3 us-gaap Class Of Warrant Or Right Number Of Securities Called By Warrants Or Rights
ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
1
CY2022Q3 us-gaap Shares Issued Price Per Share
SharesIssuedPricePerShare
0.75
CY2022Q3 us-gaap Class Of Warrant Or Right Exercise Price Of Warrants Or Rights1
ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
0.88
CY2022Q4 us-gaap Warrants And Rights Outstanding Term
WarrantsAndRightsOutstandingTerm
P5Y
CY2022Q3 us-gaap Warrants And Rights Outstanding
WarrantsAndRightsOutstanding
7752000
CY2022Q4 us-gaap Warrants And Rights Outstanding
WarrantsAndRightsOutstanding
2280000
CY2021 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
4020634
CY2021 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Grants In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod
76742
CY2021 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Expirations In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod
95626
CY2021Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Number Of Shares Available For Grant
ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant
3729204
CY2022 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod
3019065
CY2022 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
2612581
CY2022Q4 us-gaap Warrants And Rights Outstanding
WarrantsAndRightsOutstanding
2280000
CY2022Q4 us-gaap Class Of Warrant Or Right Outstanding
ClassOfWarrantOrRightOutstanding
12000000
CY2022 us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-27170000
CY2022 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
116536631
CY2022 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.23
CY2022 us-gaap Net Income Loss Available To Common Stockholders Diluted
NetIncomeLossAvailableToCommonStockholdersDiluted
-27170000
CY2022 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
116536631
CY2022 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.23
CY2021 us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-31662000
CY2021 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
111210614
CY2021 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.28
CY2021 us-gaap Net Income Loss Available To Common Stockholders Diluted
NetIncomeLossAvailableToCommonStockholdersDiluted
-31662000
CY2021 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
111210614
CY2021 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.28
CY2020Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Number Of Shares Available For Grant
ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant
6504934
CY2021 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod
1417272
CY2022 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Expirations In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod
126055
CY2022Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Number Of Shares Available For Grant
ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant
3576486
CY2020Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
8212112
CY2020Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
1.49
CY2020Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
42833712000
CY2020 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
P7Y6M3D
CY2021 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
4020634
CY2021 us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
6.22
CY2021 us-gaap Stock Issued During Period Shares Stock Options Exercised
StockIssuedDuringPeriodSharesStockOptionsExercised
557566
CY2021 us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
1.29
CY2021 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures And Expirations In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod
1417272
CY2021 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures And Expirations In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice
4.34
CY2021Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
10257908
CY2021Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
2.96
CY2021Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
3797181000
CY2021 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
P7Y5M8D
CY2022 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
2612581
CY2022 us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
0.91
CY2022 us-gaap Stock Issued During Period Shares Stock Options Exercised
StockIssuedDuringPeriodSharesStockOptionsExercised
23000
CY2022 us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
0.74
CY2022 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures And Expirations In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod
3019065
CY2022 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures And Expirations In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice
2.19
CY2022Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
9828424
CY2022Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
1.95
CY2022 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
P6Y21D
CY2022Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber
6320588
CY2022Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice
1.63
CY2022 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Weighted Average Remaining Contractual Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1
P4Y11M26D
CY2022Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Exercisable Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber
2649117
CY2022Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Exercisable Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice
2.52
CY2022 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested And Expected To Vest Exercisable Weighted Average Remaining Contractual Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1
P8Y3D
CY2022 us-gaap Share Based Compensation Shares Authorized Under Stock Option Plans Exercise Price Range Lower Range Limit
ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit
0.38
CY2022 us-gaap Share Based Compensation Shares Authorized Under Stock Option Plans Exercise Price Range Upper Range Limit
ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit
7.79
CY2022Q4 us-gaap Share Based Compensation Shares Authorized Under Stock Option Plans Exercise Price Range Number Of Outstanding Options
ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions
9828424
CY2022Q4 us-gaap Sharebased Compensation Shares Authorized Under Stock Option Plans Exercise Price Range Outstanding Options Weighted Average Exercise Price Beginning Balance1
SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1
2.96
CY2022 us-gaap Sharebased Compensation Shares Authorized Under Stock Option Plans Exercise Price Range Outstanding Options Weighted Average Remaining Contractual Term2
SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2
P7Y5M8D
CY2022Q4 us-gaap Share Based Compensation Shares Authorized Under Stock Option Plans Exercise Price Range Number Of Exercisable Options
ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions
6320588
CY2022Q4 us-gaap Sharebased Compensation Shares Authorized Under Stock Option Plans Exercise Price Range Exercisable Options Weighted Average Exercise Price1
SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1
1.61
CY2022 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
27170000
CY2021 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
31662000
CY2021 us-gaap Deferred Income Tax Expense Benefit
DeferredIncomeTaxExpenseBenefit
0
CY2022 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercises In Period Total Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue
5000
CY2022 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested In Period Fair Value1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1
5982000
CY2021 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercises In Period Total Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue
2903000
CY2021 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested In Period Fair Value1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1
4325000
CY2022 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
0.927
CY2021 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
0.890
CY2022 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
0.0245
CY2021 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
0.0063
CY2022 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
P2Y
CY2021 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
P3Y9M18D
CY2022 awh Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Weighted Average Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageFairValue
0.490
CY2021 awh Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Weighted Average Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageFairValue
3.940
CY2022 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
2410000
CY2021 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
3371000
CY2021 us-gaap Current Income Tax Expense Benefit
CurrentIncomeTaxExpenseBenefit
0
CY2022 us-gaap Current Income Tax Expense Benefit
CurrentIncomeTaxExpenseBenefit
0
CY2022 us-gaap Deferred Income Tax Expense Benefit
DeferredIncomeTaxExpenseBenefit
0
CY2022Q4 us-gaap Deferred Tax Assets Operating Loss Carryforwards
DeferredTaxAssetsOperatingLossCarryforwards
44227000
CY2021Q4 us-gaap Deferred Tax Assets Operating Loss Carryforwards
DeferredTaxAssetsOperatingLossCarryforwards
38268000
CY2022Q4 awh Deferred Tax Assets Intangible Assets Amortization
DeferredTaxAssetsIntangibleAssetsAmortization
3689000
CY2021Q4 awh Deferred Tax Assets Intangible Assets Amortization
DeferredTaxAssetsIntangibleAssetsAmortization
2404000
CY2022Q4 us-gaap Deferred Tax Assets Property Plant And Equipment
DeferredTaxAssetsPropertyPlantAndEquipment
678000
CY2021Q4 us-gaap Deferred Tax Assets Property Plant And Equipment
DeferredTaxAssetsPropertyPlantAndEquipment
633000
CY2022Q4 us-gaap Deferred Tax Assets Other
DeferredTaxAssetsOther
859000
CY2021Q4 us-gaap Deferred Tax Assets Other
DeferredTaxAssetsOther
587000
CY2022Q4 us-gaap Deferred Tax Assets Gross
DeferredTaxAssetsGross
49453000
CY2021Q4 us-gaap Deferred Tax Assets Gross
DeferredTaxAssetsGross
41892000
CY2022Q4 us-gaap Deferred Tax Assets Valuation Allowance
DeferredTaxAssetsValuationAllowance
49453000
CY2021Q4 us-gaap Deferred Tax Assets Valuation Allowance
DeferredTaxAssetsValuationAllowance
41892000
CY2022 us-gaap Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate
EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
0.21
CY2021 us-gaap Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate
EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
0.21
CY2022 us-gaap Effective Income Tax Rate Reconciliation State And Local Income Taxes
EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes
0.06
CY2021 us-gaap Effective Income Tax Rate Reconciliation State And Local Income Taxes
EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes
-0.02
CY2022 us-gaap Effective Income Tax Rate Reconciliation Change In Deferred Tax Assets Valuation Allowance
EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance
-0.28
CY2021 us-gaap Effective Income Tax Rate Reconciliation Change In Deferred Tax Assets Valuation Allowance
EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance
-0.21
CY2022 awh Effective Income Tax Rate Reconciliation Change In Fair Value Of Warrants
EffectiveIncomeTaxRateReconciliationChangeInFairValueOfWarrants
0.03
CY2022 awh Effective Income Tax Rate Reconciliation Permanent Items
EffectiveIncomeTaxRateReconciliationPermanentItems
-0.01
CY2021 awh Effective Income Tax Rate Reconciliation Permanent Items
EffectiveIncomeTaxRateReconciliationPermanentItems
0.01
CY2022 us-gaap Effective Income Tax Rate Reconciliation Other Adjustments
EffectiveIncomeTaxRateReconciliationOtherAdjustments
-0.01
CY2021 us-gaap Effective Income Tax Rate Reconciliation Other Adjustments
EffectiveIncomeTaxRateReconciliationOtherAdjustments
0.01
CY2022Q4 us-gaap Deferred Tax Assets Valuation Allowance
DeferredTaxAssetsValuationAllowance
49500000
CY2021Q4 us-gaap Deferred Tax Assets Valuation Allowance
DeferredTaxAssetsValuationAllowance
41900000
CY2020Q4 us-gaap Unrecognized Tax Benefits
UnrecognizedTaxBenefits
10517000
CY2021 awh Unrecognized Tax Benefits Return To Provision True Up
UnrecognizedTaxBenefitsReturnToProvisionTrueUp
-9000
CY2021 us-gaap Unrecognized Tax Benefits Increases Resulting From Current Period Tax Positions
UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions
508000
CY2021 us-gaap Unrecognized Tax Benefits Reductions Resulting From Lapse Of Applicable Statute Of Limitations
UnrecognizedTaxBenefitsReductionsResultingFromLapseOfApplicableStatuteOfLimitations
435000
CY2021Q4 us-gaap Unrecognized Tax Benefits
UnrecognizedTaxBenefits
10581000
CY2022 us-gaap Unrecognized Tax Benefits Increases Resulting From Current Period Tax Positions
UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions
435000
CY2022 us-gaap Unrecognized Tax Benefits Reductions Resulting From Lapse Of Applicable Statute Of Limitations
UnrecognizedTaxBenefitsReductionsResultingFromLapseOfApplicableStatuteOfLimitations
785000
CY2022Q4 us-gaap Unrecognized Tax Benefits
UnrecognizedTaxBenefits
10231000
CY2021 us-gaap Income Tax Examination Penalties And Interest Expense
IncomeTaxExaminationPenaltiesAndInterestExpense
0
CY2022 us-gaap Income Tax Examination Penalties And Interest Expense
IncomeTaxExaminationPenaltiesAndInterestExpense
0

Files In Submission

Name View Source Status
0000926617-23-000026-index-headers.html Edgar Link pending
0000926617-23-000026-index.html Edgar Link pending
0000926617-23-000026.txt Edgar Link pending
0000926617-23-000026-xbrl.zip Edgar Link pending
awh-20221231.xsd Edgar Link pending
awh-20221231x10k.htm Edgar Link pending
awh-20221231xex10_32.htm Edgar Link pending
awh-20221231xex10_33.htm Edgar Link pending
awh-20221231xex23_1.htm Edgar Link pending
awh-20221231xex31_1.htm Edgar Link pending
awh-20221231xex31_2.htm Edgar Link pending
awh-20221231xex32_1.htm Edgar Link pending
Financial_Report.xlsx Edgar Link pending
MetaLinks.json Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
awh-20221231_pre.xml Edgar Link unprocessable
awh-20221231_lab.xml Edgar Link unprocessable
awh-20221231_cal.xml Edgar Link unprocessable
awh-20221231_def.xml Edgar Link unprocessable
FilingSummary.xml Edgar Link unprocessable
awh-20221231x10k_htm.xml Edgar Link completed
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R36.htm Edgar Link pending
R37.htm Edgar Link pending
R38.htm Edgar Link pending
R39.htm Edgar Link pending
R4.htm Edgar Link pending
R40.htm Edgar Link pending
R41.htm Edgar Link pending
R42.htm Edgar Link pending
R43.htm Edgar Link pending
R44.htm Edgar Link pending
R45.htm Edgar Link pending
R46.htm Edgar Link pending
R47.htm Edgar Link pending
R48.htm Edgar Link pending
R49.htm Edgar Link pending
R5.htm Edgar Link pending
R50.htm Edgar Link pending
R51.htm Edgar Link pending
R52.htm Edgar Link pending
R53.htm Edgar Link pending
R54.htm Edgar Link pending
R55.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending